Evaluation of Modified Glasgow Prognostic Score for Pancreatic Cancer: A Retrospective Cohort Study

Pancreas

Volumn 45, Issue 2, 2016, Pages 211-217

  Imaoka, Hiroshi ^a   Mizuno, Nobumasa ^a   Hara, Kazuo ^a   Hijioka, Susumu ^a   Tajika, Masahiro ^a   Tanaka, Tsutomu ^a   Ishihara, Makoto ^a   Yogi, Tatsuji ^a   Tsutsumi, Hideharu ^a   Fujiyoshi, Toshihisa ^a   Sato, Takamitsu ^a   Shimizu, Yasuhiro ^a   Niwa, Yasumasa ^a   Yamao, Kenji ^a  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

Author keywords

albumin; C reactive protein; modified Glasgow prognostic score; pancreatic cancer; prognostic factor

Indexed keywords

ADULT; ARTICLE; CANCER PROGNOSIS; COHORT ANALYSIS; ELECTROCORTICOGRAPHY; EVALUATION STUDY; FEMALE; HAZARD RATIO; HUMAN; MALE; MIDDLE AGED; MODIFIED GLASGOW PROGNOSTIC SCORE; MONOTHERAPY; OVERALL SURVIVAL; PANCREAS CANCER; PRIORITY JOURNAL; PROGNOSTIC ASSESSMENT; RETROSPECTIVE STUDY; AGED; CANCER STAGING; METABOLISM; MORTALITY; OUTCOME ASSESSMENT; PANCREAS; PANCREATIC NEOPLASMS; PATHOLOGY; PROCEDURES; PROGNOSIS; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; STATISTICS AND NUMERICAL DATA; SURVIVAL ANALYSIS;

C REACTIVE PROTEIN; SERUM ALBUMIN;

AGED; C-REACTIVE PROTEIN; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; OUTCOME ASSESSMENT (HEALTH CARE); PANCREAS; PANCREATIC NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SERUM ALBUMIN; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS;

EID: 84955655029     PISSN: 08853177     EISSN: 15364828     Source Type: Journal    
DOI: 10.1097/MPA.0000000000000446     Document Type: Article

References (28)

1. Siegel R, Ma J, Zou Z, Cancer statistics, 2014. CA Cancer J Clin. 2014; 64: 9-29.
2. Gong Z, Holly EA, Bracci PM,. Survival in population-based pancreatic cancer patients: San Francisco Bay area, 1995-1999. Am J Epidemiol. 2011; 174: 1373-1381.
3. Luo J, Xiao L, Wu C, The incidence and survival rate of population-based pancreatic cancer patients: Shanghai Cancer Registry 2004-2009. PLoS One. 2013; 8: e76052.
4. Garcea G, Ladwa N, Neal CP, Preoperative neutrophil-to-lymphocyte ratio (NLR) is associated with reduced disease-free survival following curative resection of pancreatic adenocarcinoma. World J Surg. 2011; 35: 868-872.
5. Jamieson NB, Denley SM, Logue J, A prospective comparison of the prognostic value of tumor-and patient-related factors in patients undergoing potentially curative surgery for pancreatic ductal adenocarcinoma. Ann Surg Oncol. 2011; 18: 2318-2328.
6. Smith RA, Bosonnet L, Raraty M, Preoperative platelet-lymphocyte ratio is an independent significant prognostic marker in resected pancreatic ductal adenocarcinoma. Am J Surg. 2009; 197: 466-472.
7. Moore MJ, Goldstein D, Hamm J, Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007; 25: 1960-1966.
8. Conroy T, Desseigne F, Ychou M, FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011; 364: 1817-1825.
9. Von Hoff DD, Ervin T, Arena FP, Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013; 369: 1691-1703.
10. McMillan DC, Crozier JE, Canna K, Evaluation of an inflammation-based prognostic score (GPS) in patients undergoing resection for colon and rectal cancer. Int J Colorectal Dis. 2007; 22: 881-886.
11. Ishizuka M, Nagata H, Takagi K, Influence of inflammation-based prognostic score on mortality of patients undergoing chemotherapy for far advanced or recurrent unresectable colorectal cancer. Ann Surg. 2009; 250: 268-272.
12. Kishiki T, Masaki T, Matsuoka H, Modified Glasgow prognostic score in patients with incurable stage IV colorectal cancer. Am J Surg. 2013; 206: 234-240.
13. Leitch EF, Chakrabarti M, Crozier JE, Comparison of the prognostic value of selected markers of the systemic inflammatory response in patients with colorectal cancer. Br J Cancer. 2007; 97: 1266-1270.
14. Hirashima K, Watanabe M, Shigaki H, Prognostic significance of the modified Glasgow prognostic score in elderly patients with gastric cancer. J Gastroenterol. 2014; 49: 1040-1046.
15. Jiang X, Hiki N, Nunobe S, Prognostic importance of the inflammation-based Glasgow prognostic score in patients with gastric cancer. Br J Cancer. 2012; 107: 275-279.
16. Nozoe T, Iguchi T, Egashira A, Significance of modified Glasgow prognostic score as a useful indicator for prognosis of patients with gastric carcinoma. Am J Surg. 2011; 201: 186-191.
17. Jeong JH, Lim SM, Yun JY, Comparison of two inflammation-based prognostic scores in patients with unresectable advanced gastric cancer. Oncology. 2012; 83: 292-299.
18. Barthel F, Royston P,. Graphical representation of interactions. Stata J. 2006; 6: 348-363.
19. Raut CP, Tseng JF, Sun CC, Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Ann Surg. 2007; 246: 52-60.
20. Riediger H, Keck T, Wellner U, The lymph node ratio is the strongest prognostic factor after resection of pancreatic cancer. J Gastrointest Surg. 2009; 13: 1337-1344.
21. Slidell MB, Chang DC, Cameron JL, Impact of total lymph node count and lymph node ratio on staging and survival after pancreatectomy for pancreatic adenocarcinoma: a large, population-based analysis. Ann Surg Oncol. 2008; 15: 165-174.
22. Luttges J, Schemm S, Vogel I, The grade of pancreatic ductal carcinoma is an independent prognostic factor and is superior to the immunohistochemical assessment of proliferation. J Pathol. 2000; 191: 154-161.
23. Imaoka H, Shimizu Y, Mizuno N, Clinical characteristics of adenosquamous carcinoma of the pancreas: a matched case-control study. Pancreas. 2014; 43: 287-290.
24. Kasymjanova G, MacDonald N, Agulnik JS, The predictive value of pre-treatment inflammatory markers in advanced non-small-cell lung cancer. Curr Oncol. 2010; 17: 52-58.
25. La Torre M, Nigri G, Cavallini M, The Glasgow prognostic score as a predictor of survival in patients with potentially resectable pancreatic adenocarcinoma. Ann Surg Oncol. 2012; 19: 2917-2923.
26. Wang DS, Luo HY, Qiu MZ, Comparison of the prognostic values of various inflammation based factors in patients with pancreatic cancer. Med Oncol. 2012; 29: 3092-3100.
27. Burris HA 3rd, Moore MJ, Andersen J, Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997; 15: 2403-2413.
28. Ueno H, Ioka T, Ikeda M, Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study. J Clin Oncol. 2013; 31: 1640-1648.